Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Tom Shaughnessy is owner of SecretCaps.com, an independent investor and analyst. He has been investing in the stock market since the age of twelve. His style is comprehensive and includes multi-layered research on a concentrated set of stocks. Tom enjoys constructive dialogue regarding various investment ideas and theories. Tom enjoys intensive research on prospective investments. This includes valuation estimates and modeling, CEO and management interviews, product and expansion overviews, future prospects, financial analysis and the current state of affairs at the company. Moreover, Tom's articles have a focus on micro-cap companies whose potential have flown under the radar. In his leisure time Tom enjoys playing racquetball on a competitive level. Twitter: Toms_119
Arrow Loop Research delivers a value-based investing newsletter called Arrow Loop Research's Actionable Ideas for Maximizing Returns. Sign up for a free trial here. Arrow Loop Research provides general investment advice. Nothing contained in the newsletter should be construed as specific investment advice.
Dr. Paul Price, writer of Arrow Loop Research's premium research service, writes about stocks, options and the market every weekday on Real Money Pro, a subscription site on TheStreet.com. Paul has been a speaker at the International Traders Expo in New York City and the Options and Forex Expo in Las Vegas. He also gives investment seminars for subscribers of TheStreet's multiple subscription sites. Dr. Price is a featured contributor on Market Shadows.com, GuruFocus.com and TalkMarkets.com.
Paul followed his passion for the stock market when he gave up his career as a dentist to join Merrill Lynch back in April of 1987. Paul feels that he is “living the dream” of many investors. He stopped “going to work” when he turned 50 (in the year 2000) and has been living well from his investment returns ever since.
Paul enjoys sharing the accumulated market wisdom he’s gained from years in the markets. He loves analyzing companies and picking individual stocks. According to Paul, once you know what equities to buy, option writing (selling covered calls and/or naked puts) just flows naturally. They serve as ways to impose investment discipline and create income while providing an extra margin of safety versus plain vanilla share ownership. Paul’s articles stand out for their unique graphics which are packed with information which distills our TMI (too much information) world into easy to understand, and actionable advice.
Jason Bond is an American stock trader, entrepreneur, and small cap expert. Jason teaches small cap swing trading at Jason Bond Picks. He is best known for his 2013 swing trading performance tripling the S&P 500 in the portfolio he manages. Jason’s small cap swing trading ideas are widely published on numerous financial sites and blogs. Prior to teaching small cap swing trading in 2011, Jason taught for the Webster Central School District in NYS from 2001 - 2011. Jason’s trading strategy attempts to capture gains in a stock within one to four days. He uses technical analysis to look for stocks with short-term price momentum. Jason is interested in the fundamental value of stocks but puts emphasis on price trends and patterns.
Markman Advisors specializes in the strategic analysis of investment opportunities presented by intellectual property—and in particular, patent—litigation activities. We are all USPTO-registered patent attorneys with decades of combined experience in patent litigation, licensing and procurement. After many years practicing at some of the world’s largest and well-known law firms, we established and now run a premier intellectual-property boutique law firm, where we continue to practice patent litigation. We have litigated numerous high-stakes patent cases in federal district courts throughout the country, as well as at the appellate level before the Federal Circuit. We are also experienced in USPTO proceedings, and have advised clients across a wide swath of technical areas with respect to patent-related matters. Our base of former and current legal clients is diverse, from technology start-ups to some of the world’s largest and most well-known corporations. Collectively, we have led those clients through numerous Markman hearings, summary judgment motions, trials and appeals – on both the offensive and defensive sides of a case. Our patent litigation experience, coupled with our knowledge of the market for "patent play" stocks, is the alpha we bring to each patent litigation-driven investment opportunity.
Patent News. We publish all the latest insights about patents and patent cases and ways to make profits from trading/investing in these up and coming companies.
Feel free to contact with any questions.
We await your reply.
CFA, Alternative investment professional, equity bias but cap structure agnostic. I spent a year on the PHLX options exchange, and worked as an integral member of the investment committee of a medium sized L/S hedge fund in NY, as well as their head-trader, for 6 years.
My personal bias is towards special situations, and smaller cap names, . I use a value-investing orientation, though I try to marry actual catalysts and a top-down understanding to any thesis I present.
Currently going for MBA in finance. Personally invest mainly in biotechs and all opinions are my own. Follow me @KeithStokes14 on twitter (I discuss trades and companies, mainly small-cap biotechs).
I am an active husband, father, lawyer (more than 24 years, how time flies), and investor. I believe in contrarian investing, i.e., going where the crowd isn't. I believe that successful investing, like successful living, requires equal parts listening and evaluating, followed by independent decision making.
I work in the medical and healthcare field so my focus is mainly on Biotech stocks. I try to find the next Celgene, the next Pharamcylics if possible.
Been a trader and investor for 13 years.
Love the game, and I hope you enjoy my articles on here.
Good luck with your investments and I look forward to all of your comments and suggestions.
Read more here
I am an American trader and a Vanderbilt University alumnus currently living in San Francisco. I'm mostly interested in income investing using dividends, preferred stocks and other debt instruments, and pair trading.
I fundamentally analyze every business from the top down.
In my personal life, I have a strong Jewish faith and enjoy playing Scrabble and entrepreneurship.
I am a full-time investor focused on managing my own portfolio and living off the capital gains. I tend to analyze small-cap stocks, especially companies that present an attractive risk/reward opportunity. I'm not afraid to take risks if the return possibilities justify it.
Helix Investment Research was founded in July 2011 by Ivan Deryugin, and focuses on leveraging secular global trends, across a variety of sectors, in order to generate long-term outperformance.
AtonRa Partners is an independent equity research and asset management company. Our approach is based on a deep knowledge and understanding of market dynamics and focuses on adding value to clients' portfolios via thoroughly checked proprietary information and data sources. We cherish a "speak our mind" approach in our reports (accessible at http://www.atonra.ch). We are also part of Euro IRP ("European Independent Research Providers", see http://www.euroirp.com/members/).
Spent my entire 28 year career on Wall Street with over a decade at Bear Stearns. No "Wall Street Titan" in real life but WST is just a catchy alias I use on SA. Over the past decade, I have gained a significant amount of knowledge regarding the stem cell sector and have launched a premium service covering this long out of favor but exciting area.
Wall Street Titan Research
As I'm a long-term investor, I'll highlight some stockpicks which will have a 5-7 year investment horizon. As I strongly believe a portfolio should consist of a mixture of dividend-paying stocks and growth stocks, my articles will reflect my thoughts on this mixture.
My name is Mike Allison. My wife and I have recently moved to Frankfurt, Germany, after having lived and worked in Greater China from 2001. I am still gamefully employed as a corporate consultant and business coach. A majority of our clients are in the big pharma sector and include companies such as Bayer, Johnson and Johnson, Merck, Gilead.
Most recently I have been investing in dividend paying stocks as well as value and deep value stocks. I also have some precious metals miners in my portfolio as well as one uranium producer and a nano technology solar stock.
All of my knowledge regarding trading and the markets has been gained from reading newsletters, belonging to sites such as Seeking Alpha, and learning from people with far more knowledge and experience than myself.
Chief Market Strategist at www.buysellshort.net. Learn how to make a living trading small and midcap stocks
Additional Disclaimer: I may buy and sell any positions mentioned in any article at any time.
JG Investment Research delivers a complete and detailed investment analysis mostly on small and mid-cap companies on Seeking Alpha. We have won several awards, including being named as one of TipRanks' “Top 100” financial bloggers with an average return per recommendation at 25.4%.